Novartis is a Swiss multinational pharmaceutical corporation headquartered in Basel. The company was formed in 1996 through the merger of Ciba-Geigy and Sandoz and is one of the world’s largest pharmaceutical companies.
Novartis acquires UK biotech Myricx Bio for up to $1.5B, gaining a novel NMTi ADC payload platform and two lead assets targeting B7-H3 and HER2. The deal includes $1.1B upfront with $400M in milestones, expected to close in H2 2026.
Anthropic announced it will run its own preclinical drug-discovery programs for neglected and rare diseases and launched Claude Science, an AI workbench for researchers. The company has not named specific diseases or detailed how it would bring candidates to market.
Sanofi announces leadership transition with CEO departure and interim appointment, while reporting key regulatory milestones including FDA Breakthrough Therapy designation for venglustat and expanded Dupixent approvals. The company advances an observational RSV study in Australia and outlines strategic initiatives in AI drug discovery and potential consumer healthcare spin-off.
Novartis has announced three separate partnership deals worth over $5 billion combined with Antares Therapeutics, Orionis Biosciences, and Unnatural Products. The agreements target undruggable cancers, molecular glue drugs, and cardiovascular therapies respectively using each partner's proprietary platforms.
Switzerland will vote on June 14 on a proposal to cap its population at 10 million by 2050, which would restrict migration and potentially end EU free-movement agreements. Corporate leaders and business groups warn of severe labor shortages and economic damage. Polls show the vote is closely contested, with the population having grown rapidly in recent decades.
A Washington federal judge declined to block a state law expanding 340B drug pricing discounts, rejecting Novartis and AbbVie's arguments that it illegally adds to their obligations under the federal program aimed at protecting low-income patients.
Global drugmakers are expanding rare disease research investment in Brazil, attracted by new regulations, genetic diversity, and the public healthcare system's data capabilities. Major companies including AstraZeneca, Biogen, and Roche have committed significant clinical research budgets to the country. Despite this progress, advocates warn that a significant global funding gap persists, with 95% of rare diseases still lacking an FDA-approved treatment.
The FDA is receiving extensive industry feedback on three regulatory initiatives: draft guidance for using new approach methodologies to reduce animal testing, the Commissioner's National Priority Voucher pilot program, and a proposed rule to update the National Drug Code format. Stakeholders are urging revisions to the NAMs guidance, improvements to the CNPV program, and timely finalization of the NDC rule to avoid disruptions.
Novartis expands US radioligand manufacturing with new Texas and North Carolina facilities to bolster domestic production of cancer treatments. Telix Pharmaceuticals reports positive Phase 3 prostate cancer trial data and maintains 2026 revenue guidance of US$950-970 million.
Two new interchangeable Lucentis biosimilars — Lupin's Ranluspec and Formycon/Bioeq's Nufymco — have received FDA approval, while Xbrane's Lucamzi is under review with an October target date. The Lucentis global market was valued at $630 million in 2024.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07549646 |
24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07549139 |
Overcoming Racial Disparities in Screening Mammography |
NOT_YET_RECRUITING | NA |
| NCT07543822 |
24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07538401 |
ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07493408 |
Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML |
NOT_YET_RECRUITING | PHASE2 |
| NCT07443137 |
CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) |
NOT_YET_RECRUITING | PHASE1 |
| NCT07434180 |
Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary |
NOT_YET_RECRUITING | PHASE2 |
| NCT07431931 |
Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria |
NOT_YET_RECRUITING | NA |
| NCT07415824 |
Multiple Sclerosis Implementation Network (Registry) |
RECRUITING | |
| NCT07382414 |
Electronic Letters to Improve Patient Activation in IHD: The NUDGE-IHD Trial |
NOT_YET_RECRUITING | NA |
